Cisplatin

Generic Name: Cisplatin

Brand Names: Platinol

Drug Type: Small Molecule

Chemical Formula: Cl_₂H_₆N_₂Pt

CAS Number: 15663-27-1

Unique Ingredient Identifier: Q20Q21Q62J

Background: Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication: For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions: Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer

Associated Therapies: -

Clinical Trials

Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer

Phase 2

Withdrawn

Conditions: Lung Non-Small Cell Carcinoma
Stage I Lung Cancer AJCC v8
Stage IA1 Lung Cancer AJCC v8
Stage IA2 Lung Cancer AJCC v8
Stage IA3 Lung Cancer AJCC v8
Stage IB Lung Cancer AJCC v8
Stage II Lung Cancer AJCC v8
Stage IIA Lung Cancer AJCC v8
Stage IIB Lung Cancer AJCC v8
Stage IIIA Lung Cancer AJCC v8

Interventions: Biological: Pembrolizumab
Drug: Cisplatin
Procedure: Therapeutic Conventional Surgery
Drug: Pemetrexed
Drug: Pemetrexed Disodium

First Posted Date: 2019-08-20

Last Posted Date: 2022-03-04

Lead Sponsor: University of California, San Francisco

Registration Number: NCT04061590

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Paricalcitol Addition to Chemotherapy in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Phase 2

Active, not recruiting

Conditions: Pancreatic Cancer

Interventions: Drug: Paclitaxel protein bound
Drug: Cisplatin
Drug: Gemcitabine
Drug: Paricalcitol

First Posted Date: 2019-08-13

Last Posted Date: 2024-11-05

Lead Sponsor: Barts & The London NHS Trust

Target Recruit Count: 14

Registration Number: NCT04054362

Locations: 🇬🇧
Barts Health NHS Trust, London, London, Greater, United Kingdom

Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors

Phase 1

Completed

Conditions: Locally Advanced and Metastatic Solid Tumors

Interventions: Drug: Ociperlimab
Drug: Tislelizumab
Drug: Paclitaxel
Drug: Pemetrexed
Drug: Nab paclitaxel
Drug: 5fluorouracil
Drug: Carboplatin
Drug: Cisplatin
Drug: Etoposide
Drug: Oxaliplatin
Drug: Capecitabine

First Posted Date: 2019-08-07

Last Posted Date: 2024-11-29

Lead Sponsor: BeiGene

Target Recruit Count: 449

Registration Number: NCT04047862

Locations: 🇺🇸
University of Kansas Medical Center Research Institute, Kansas City, Kansas, United States
🇦🇺
St Vincents Hospital, Fitzroy, Victoria, Australia
🇨🇳
Beijing Tongren Hospital, Cmu, Beijing, Beijing, China

and more 26 locations

Adjuvant PIPAC in Gastric Cancer Patients

Phase 1

Completed

Conditions: Gastric Adenocarcinoma
Gastric Cancer

Interventions: Drug: Doxorubicin
Drug: Cisplatin

First Posted Date: 2019-08-06

Last Posted Date: 2022-10-06

Lead Sponsor: Michael Bau Mortensen

Target Recruit Count: 20

Registration Number: NCT04047004

Locations: 🇩🇰
Odense PIPAC Center, Department of Surgery, Odense University Hospital, Odense, Denmark
🇸🇪
Karolinska University Hospital, Stockholm, Sweden

Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer

Phase 2

Active, not recruiting

Conditions: Stage II Laryngeal Cancer AJCC v8
Stage III Laryngeal Cancer AJCC v8
Laryngeal Squamous Cell Carcinoma

Interventions: Drug: Carboplatin
Drug: Cisplatin
Drug: Docetaxel
Biological: Pembrolizumab

First Posted Date: 2019-07-24

Last Posted Date: 2024-07-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 27

Registration Number: NCT04030455

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer

Phase 3

Active, not recruiting

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Biological: Nivolumab
Drug: Carboplatin
Drug: Cisplatin
Drug: Paclitaxel
Drug: Placebo
Drug: Pemetrexed
Drug: Docetaxel

First Posted Date: 2019-07-19

Last Posted Date: 2024-07-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 461

Registration Number: NCT04025879

Locations: 🇺🇸
Local Institution - 0086, Traverse City, Michigan, United States
🇺🇸
Local Institution - 0103, Fredericksburg, Virginia, United States
🇨🇦
Local Institution - 0062, Oshawa, Ontario, Canada

and more 102 locations

FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery

Not Applicable

Recruiting

Conditions: Cervical Cancer

Interventions: Drug: Cisplatin
Drug: Carboplatin
Drug: Paclitaxel
Procedure: Trachelectomy

First Posted Date: 2019-07-11

Last Posted Date: 2023-11-07

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 90

Registration Number: NCT04016389

Locations: 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇺🇸
MD Anderson Cancer Centre, Houston, Texas, United States
🇨🇦
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

and more 1 locations

Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)

Phase 3

Active, not recruiting

Conditions: Biliary Tract Carcinoma

Interventions: Biological: Pembrolizumab
Drug: Gemcitabine
Drug: Placebo
Drug: Cisplatin

First Posted Date: 2019-07-01

Last Posted Date: 2024-11-18

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 1069

Registration Number: NCT04003636

Locations: 🇺🇸
UCLA Hematology/Oncology - Santa Monica ( Site 0014), Los Angeles, California, United States
🇺🇸
Hartford Hospital ( Site 0057), Hartford, Connecticut, United States
🇺🇸
Winship Cancer Institute of Emory University ( Site 0013), Atlanta, Georgia, United States

and more 182 locations

PIPAC With Nab-paclitaxel and Cisplatin in Peritoneal Carcinomatosis

Phase 1

Active, not recruiting

Conditions: Peritoneal Carcinomatosis

Interventions: Drug: Nab paclitaxel
Drug: Cisplatin

First Posted Date: 2019-06-27

Last Posted Date: 2024-05-24

Lead Sponsor: University Hospital, Geneva

Target Recruit Count: 18

Registration Number: NCT04000906

Locations: 🇨🇭
University Hospital, Lausanne, Lausanne, Vaud, Switzerland
🇨🇭
University Hospital, Geneva, Geneva, Switzerland

Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma

Phase 2

Active, not recruiting

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: PD-1 blocking antibody
Drug: Gemcitabine
Drug: Cisplatin
Radiation: Intensity-modulated radiotherapy

First Posted Date: 2019-06-13

Last Posted Date: 2024-05-29

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 152

Registration Number: NCT03984357

Locations: 🇨🇳
Xiangya Hospital Central South University, Changsha, Hunan, China
🇨🇳
Fujian Provinve Cancer Hospital, Fuzhou, Fujian Provinve, China
🇨🇳
Cancer Hospital of Guizhou Medical University, Guiyang, Guizhou, China

and more 3 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy